It is a great pleasure to welcome you all at 14th European Oncology Conference 2026, which is going to be held during March 06-07, 2026 at Barcelona, Spain, with a theme “Next-Gen  Oncology From Bench to Bedside” which includes  keynote presentations, speaker talks, Exhibition, Symposium, Workshops, Speaker sessions. European Oncology Conference 2026 brings together individuals who have an interest in different fields of cancer research and can attend Oncology Researchers, Doctors Scientists, Academic researchers, Industry specialists, Scholars in the field of Oncology, Hematology, Surgery, Nursing, Radiology, Paediatrics, Advocacy, Cancer Researchers, Cancer research Faculty, Medical Colleges, Radiologists, Chemo therapists, Pathologists, Business Entrepreneurs and Healthcare Industries.

The prime aim of the Conference is to promote new research concept in Education and Research in all fields and disciplines of cancer research, oncology, cancer therapy, cancer treatment, on-going and future perspectives. The presence of more than 70 delegates from different countries is expected. European Oncology Conference 2026 aims to provide an opportune forum and vibrant platform for Researchers, Academicians, Scientists and Industrial Practitioners to share their ideas, original research work. This virtual conference provides an international forum for the exchange of ideas, discussions on research results and the presentation of theoretical and practical applications in these domains. The objective of this virtual conference is to create awareness and to provide a perfect platform for the participants to upgrade their knowledge and experience and to discuss on the ways to foster the exchange of concepts, prototypes, research ideas and the research work. This conference reflects the current focus of global research, recent developments, interdisciplinary research and practices in the fields of cancer research, oncology, cancer therapy, and cancer treatment, on-going and future perspectives.

“Meet Inspiring Speakers and Experts at our Scientific Meditech Conferences/Webinars with Unique Opportunity in Science, Medical and Technology field, which gives the online visibility to the Speakers, Experts and young researchers,”

Speaker Benefits at European Oncology Conference 2026

• Access to All Sessions Offline and Online
• Handbook & Conference Kit
• Certificate of Presentation by International Organizing Committee (IOCM)
  
• Convenient to all Scientists, researchers and eminent professors
• Visibility of your profile across world
• Creation one web page for each participants

For any further information/queries, please send mail at:

oncology@scientificmeditech.com; inquiry@scientificmeditech.com

13th European Oncology Conference 2025,
April 23-24, 2025 | Dubai, UAE 

Past Conference Report:

We gratefully thank all our wonderful Keynote Speakers, Chairperson, Plenary Speakers, Poster Presenter, Delegates, Students, Media Partners and Associations for making 13th European Oncology Conference 2025, April 23-24, 2025 | Dubai, UAE  a grand success.

Scientific Meditech expresses its gratitude to the Webinar Chair, namely Prof. Jianqing Lin, George Washington University School of Medicine and Health Sciences, USA | Prof. Jian Wu, Fudan University, China & Prof. Helidon Nina, Tirana University, Albania and a special thanks to our Moderator Dr. Purnima Rajkarnikar Sthapit,  Tilganga Institute of Ophthalmology, Kathmandu, Nepal  for the support and coordinate during the sessions. We are indebted to your support.

A very special thanks to Prof. Wei Qiu,  Loyola University Chicago, USA & Prof. Jose Oscar Gutiérrez-M, Universidad del Valle, Colombia  for the valuable presence and support.

Scientific Meditech would like to convey a warm gratitude and special thanks to below Keynote & Plenary Speakers of 13th European Oncology Conference 2025.

Dr. Rubia Isler Mancuso, University of Campinas, Brazil

Dr. Anita Grigoradis, Breast Cancer Unit,  King’s College London,  UK

Dr. Mark Cronshaw, University of Birmingham, UK

Dr. Jianqing Lin, George Washington University School of Medicine & Health Sciences, USA

Dr.Vikas Kundra, M.D. Anderson Cancer Center, USA   

Dr. Lucia Moletta, University of Padova, Italy     

Dr. Qingbin Cui, Sun Yat-sen University Cancer Center, China

Dr. Linoy Mehazri,  Bar-Ilan University, Israel    

Dr. Jian Wu, Fudan University, China

Dr. Wei Qiu,  Loyola University Chicago, USA    

Dr. Norrina Binti Jamaluddin, Malaysian Health Technology Assessment (MaHTAS), Malaysia

Dr. Nurfarah Aqilah Ahmad Nizam, Malaysian Health Technology Assessment (MaHTAS), Malaysia

Dr. Sanjeev Chawla, Perelman School of Medicine at University of Pennsylvania, USA

Dr. Valerii Orel, National Cancer Institute of Ukraine, Ukraine

Mr. Vignesh Sivaganesh, Philadelphia College of Osteopathic Medicine, USA

Dr. Huadong Pei, The George Washington University School of Medicine and Health Science, USA      

Dr. Cole Bergeron,  Louisiana State University Shreveport, USA

Dr. Purnima Rajkarnikar Sthapit, Tilganga Institute of Ophthalmology, Kathmandu, Nepal

Dr. Cristina Romei, University of Pisa, Italy  

Dr. Sweta Sharma Saha,  Newcastle University, UK

Dr. Jose Oscar Gutiérrez-M, Universidad del Valle, Colombia

Dr. Mónica J Basante-Romo, Universidad del Valle, Colombia

Dr. Rubén Camargo- Amado, Universidad del Valle, Colombia

Dr. Marzieh Ehsani , Institute of Human Genetics, Jena University Hospital, Germany

Dr. Konstantina Karamanou,  University of Patras, Greece

Dr. Xiong Zhang,  University of California, USA

Dr. Marwa Elsayed , University of Missouri Kansas City, USA

Dr. Ves-Losada Ana, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), Argentina

Dr. Ricardo Fernández Ferreira , Médica Sur Hospital, Mexico

Dr. Helidon Nina, Tirana University, Albania

Dr. Carlos Pérez-Sánchez, Reina Sofia University Hospital, Spain

Dr. Abdelilah Ghannam, Mohammed V University of Rabat Avenue des Nations Unies, Morocco

Dr. El Hadji Seydou MBAYE,  International Agency for Research on Cancer, France.

Dr. Nancy K Lonsdorf, Maharishi International University, USA & Many more…

Scientific Sessions and Tracks

Session 01: Cancer Research
Session 02: Cancer Treatment, Therapies and Nursing
Session 03: Cancer Care and management
Session 04: Drug Design and Clinical Trials for Cancer
Session 05: Cancer Drugs and Vaccines
Session 06: Cancer Diagnostics and Staging
Session 07: Oncology
Session 08: Types of Cancer Therapies and applications
Session 09: Oncologists- Types and roles
Session 10: Recent Research and Innovations in Oncology
Session 11: On-going and future research in cancer treatment
Session 12: Types of Cancer and their Immunotherapy
Session 13: Oncology Biomarkers
Session 14: Breast Cancer
Session 15: Lung Cancer
Session 16: Ovarian and Cervical Cancer
Session 17: Skin Cancer
Session 18: Modern advancements in Oncology Diagnostics Technologies
Session 19: Cancer Surgery & Biopsy for cancer
Session 20: Cancer: Lifestyle and Nutrition
Session 21: Cancer diagnostic techniques
Session 22: Traditional therapy for cancer treatment
Session 23: Brain Cancer
Session 24: Case Study Reports Cancer
Session 25: Prevention and Healthy Living
Session 26: Cancer imaging test
Session 27: Cancer Pharmacology
Session 28: Pharmaceutical Oncology

Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other cause.

The investigation of the malignancy gene helps in targeting the mutation directly in order to treat the disease or prevent it from growth. Advanced genomic testing is helpful in recognizing the DNA variations which can cause the gene alterations resulting in the formation of cancer cells. Genomic testing help oncologists to study the about individual genomic alterations that are unique for each individual, hence preparing personalized medicine to target such mutation cells will be forever helpful in treating the disease.

The growing studies and successful researches in the field have given rise to its market value and is proceeding on its way to grab the entire market and save it from the deadly cancer disease. The global cancer genomics size was valued to be $9216 million in 2014 and grew to be $17.8 billion in 2028. The rising investments by governments in biotech, growth in the number of genomics projects, decreasing sequencing cost and the increasing R&D activities for the development of novel therapies are serving as the main pillars for the growth of the oncogenomics market.

Target Audience

Cancer 2025 brings together individuals who have an interest in different fields of cancer research and can attend Oncology Researchers, Doctors Scientists, Academic researchers, Industry specialists, Scholars in the field of Oncology, Hematology, Surgery, Nursing, Radiology, Paediatrics, Advocacy, etc Cancer Researchers, Cancer research Faculty, Medical Colleges, Radiologists, Chemo therapists, Pathologists, Business Entrepreneurs Pharmaceutical Industries, Healthcare Industries.

Opportunities for Webinar Attendees